Efesa Achieves Regulatory Approval in Cambodia, Paving the Way for Commercial Availability in 2026

The approval reflects the recognition of Efesa’s clinical value and safety profile, reinforcing our commitment to providing high-quality therapies that address important patient needs.

With regulatory clearance now secured, Efesa is moving forward with preparation for market introduction. Commercial availability in Cambodia is estimated to begin in 2026, following completion of distribution planning, healthcare professional engagement, and other launch readiness activities.

Efesa remains committed to working closely with healthcare stakeholders in Cambodia to ensure a smooth and effective product rollout that supports improved patient outcomes.